BE BEAM Beam Therapeutics Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions

Author clarifies personal history with Sophon and Beam, defends Beam's treasury and token burns, but does not express a forward-looking trade view.

Buy BEAM as a beneficiary of quantum computing and AI-driven biotech breakthroughs; author sees these technologies as catalysts for transformative drug discovery including cancer cures and regenerative medicine.

Author flags BEAM as facing difficulty in an IP theft dispute with BOLD, describing the situation as egregious; no explicit directional position stated.

Beam is too speculative, avoid.

In the outro, Becky Quick teases the next episode featuring a child who received a "personalized CRISPR-based gene editing therapy" that likely saved his life. While a teaser, this highlights the shift of CRISPR technology from theoretical research to applied clinical success ("miracles"). Positive real-world outcomes in rare diseases validate the platforms of major gene-editing companies, justifying premium valuations for their pipelines. Long the CRISPR innovators as clinical validation accelerates. Regulatory hurdles; high cost of personalized therapies limiting total addressable market (TAM).